Wednesday, July 31, 2013 10:32:11 AM
Wounds had been present for an average of over 21 weeks when treatment with EpiFix was initiated. When reporting outcomes at the predetermined study intervals of 4, 6 and 12 weeks, 55% of the patients achieved complete healing within 4 weeks, 64% within 6 weeks, and 91% within 12 weeks. Although 12 weeks was the predetermined study interval, the 91% complete healing outcome was actually achieved in 9 weeks.
from the study...
Discussion
This is the ?rst randomised controlled trial in the USA comparing standard of care versus standard of care plus advanced
therapy using a dehydrated human amniotic membrane product (EpiFix) in patients with a long-standing diabetic ulcer.
Patients in the study sample treated with EpiFix had significantly greater rates of healing and healed in a more rapid
fashion than those patients receiving standard of care alone.
Human amniotic membrane has been scienti?cally studied
to examine how it contributes to the healing process in
wounds. Amniotic membrane is composed principally of
three types of material: structural collagen and extracellular
matrix, biologically active cells and a large number of
important regenerative molecules (21). Collagen types IV,
V and VII provide an important substrate, which is not only
important for the structural integrity of the membrane but
also facilitates wound healing and cellular ingrowth. There
is clear evidence that many of these molecules interact with
one another in a highly complex milieu of bioregulation
that requires the presence of membranes, individual growth
factors and interactions that upregulate and downregulate the
various regenerative processes of healing (22).
Human amniotic membrane has been found to have a
number of characteristics that make it uniquely suited to
wound healing. For example, previous studies have shown
that amniotic membrane:
• provides a matrix for cellular migration and proliferation (15),
• promotes increased healing and enhancement of the
wound healing process (23),
• is non immunogenic (24),
• reduces in?ammation (25),
• reduces scar tissue (26),
• has antibacterial properties (27,)
• reduces pain at the site of application (29,30),
• provides a natural biological barrier (29,31),
• contains a number of essential growth factors and
cytokines (32).
Overall, amniotic membrane has potential uses in a variety
of other wound healing applications in addition to cutaneous
wounds including applications in periodontology, otorhinolaryngology and general surgery. The material appears to be
safe in its overall use and contributes signi?cantly to the
regeneration of various soft tissues (31,33,34).
Models of cost-effectiveness in wound care have been
postulated and developed by a number of authors. Data from
registries often are used to calculate the health care claims
costs of wound care, and are expressed in terms of cost
to heal, hospitalisation costs or overall medical care costs
(13,35). While health economists focus on these tangible
costs of wound management, the true economic analyses also
develop from productivity, quality of life and related issues
as well (36). In order for an advanced therapy such as EpiFix
to be seen as an acceptable treatment option it must be
clinically ef?cacious, operationally ef?cient for the clinician,
improve the patients’ quality of life and be cost-effective. A
treatment that reduces healing time while requiring minimal
dressing changes with a low need for reapplication meets these
requirements.
Dehydrated amniotic membrane material is operationally
ef?cient in that it can be transported and stored at room
temperature for long periods of time up to 5 years, thus
minimising the need for complex policies for receiving
and storing the material. In addition, the added expense of
subzero refrigeration or short storage life that often leads
to wasted product is no longer a consideration or expense.
Handling characteristics of the EpiFix material permit easy
retrieval and use and minimise time for application, allowing
for more ef?cient utilisation of the clinicians’ time and effort.
The material can be provided in a number of different sizes,
minimising the amount of waste when used on varying size
ulcers and at various stages in healing.
In this study, the overall comparison of the standard of care
with the standard of care plus dehydrated amniotic membrane
allograft re?ected an unprecedented ability of the material to
assist in the resolution of diabetic neurotrophic ulcers. The use
of the EpiFix material obviated at least six dressing changes
by the patient per week and any associated home health care
visits. The EpiFix material, placed on an every other week
regimen, aggressively closed the wounds under consideration
in a far shorter time than standard wound treatment. Therefore,
as the allograft material is placed less frequently, and the
wounds heal more quickly than alternative therapies, the
potential for reduced cumulative as well as episode costs can
be assumed.
https://docs.google.com/viewer?url=http%3A%2F%2Fmimedx.com%2Fimages%2Fpdf%2FIWJ_Zelen_RCT_June_2013.pdf
_________________
Recent MDXG News
- EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS" • PR Newswire (US) • 09/11/2024 05:03:00 PM
- THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES' • PR Newswire (US) • 09/04/2024 08:23:00 PM
- MIMEDX to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/27/2024 12:00:00 PM
- DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT • PR Newswire (US) • 08/26/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:11:07 PM
- MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix • GlobeNewswire Inc. • 07/31/2024 08:02:00 PM
- MIMEDX Announces Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 07/31/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 08:00:39 PM
- MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports • GlobeNewswire Inc. • 07/22/2024 12:10:48 PM
- Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2024 09:58:09 PM
- MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer • GlobeNewswire Inc. • 06/26/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:00:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:30:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:20:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:15:26 PM
- MIMEDX to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/15/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 10:46:36 PM
- MIMEDX Announces First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/30/2024 08:01:00 PM
- MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30 • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
- MIMEDX Introduces E-Commerce and Account Management Platform • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:28:23 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM